Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBITDA (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of EBITDA data on record, last reported at -$69.8 million in Q4 2025.

  • For Q4 2025, EBITDA fell 37.93% year-over-year to -$69.8 million; the TTM value through Dec 2025 reached -$270.0 million, down 57.19%, while the annual FY2025 figure was -$270.0 million, 57.19% down from the prior year.
  • EBITDA reached -$69.8 million in Q4 2025 per OCUL's latest filing, down from -$68.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$17.8 million in Q1 2022 and bottomed at -$69.8 million in Q4 2025.
  • Average EBITDA over 5 years is -$34.0 million, with a median of -$21.1 million recorded in 2022.
  • Peak YoY movement for EBITDA: grew 11.84% in 2022, then tumbled 152.26% in 2024.
  • A 5-year view of EBITDA shows it stood at -$18.0 million in 2021, then fell by 7.27% to -$19.4 million in 2022, then dropped by 3.55% to -$20.0 million in 2023, then crashed by 152.26% to -$50.6 million in 2024, then tumbled by 37.93% to -$69.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$69.8 million in Q4 2025, -$68.7 million in Q3 2025, and -$67.6 million in Q2 2025.